Diane Siedlecki, MD
Internal Medicine · Providence, RINPI 1265438923
Payments from drug & device makers
Across 216 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$538
- Novo Nordisk$465
- AbbVie$463
- Amgen$310
- Viiv Healthcare Company$243
- Sanofi-aventis U.S. LLC$214
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,087100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $538 |
| Novo Nordisk | 23 | $465 |
| AbbVie(2 entities) | 22 | $463 |
| Amgen | 15 | $310 |
| Viiv Healthcare Company | 13 | $243 |
| Sanofi-aventis U.S. LLC | 11 | $214 |
| Merck | 12 | $202 |
| GSK | 13 | $202 |
| Teva Pharmaceuticals USA, Inc. | 13 | $193 |
| Pfizer | 10 | $167 |
| Nestle Healthcare Nutrition Inc. | 6 | $167 |
| Lilly USA, LLC | 5 | $106 |
| Boehringer Ingelheim | 3 | $77 |
| Amarin Pharma, Inc. | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 2 | $58 |
| Exact Sciences | 2 | $42 |
| Astellas Pharma US Inc | 3 | $40 |
| Insmed, Inc. | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Gilead | 2 | $36 |
| Abbott | 2 | $34 |
| Insightec,inc | 1 | $32 |
| Johnson & Johnson(2 entities) | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Dexcom, Inc. | 1 | $27 |
| Eisai Inc. | 1 | $27 |
| Agios Pharmaceuticals, Inc. | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Bayer | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $11 |
How this compares
$4,087 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 58 | $258,441 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 23 | $84,058 |
| EliquisApixaban | 37 | $43,158 |
| OzempicSemaglutide | 30 | $42,870 |
| ProliaDenosumab | 25 | $39,693 |
| Repatha SureclickEvolocumab | 35 | $36,476 |
| IsentressRaltegravir Potassium | 13 | $25,540 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $22,636 |
| TrulicityDulaglutide | 18 | $19,915 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $17,385 |
| Lopinavir-RitonavirLopinavir/Ritonavir | 14 | $11,608 |
| Nurtec OdtRimegepant Sulfate | 12 | $10,705 |
| XareltoRivaroxaban | 11 | $10,513 |
| JardianceEmpagliflozin | 11 | $10,010 |
| FarxigaDapagliflozin Propanediol | 11 | $9,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $36 | $342,49981 claims |
| PfizerEliquis, Nurtec Odt | $167 | $53,86449 claims |
| Novo NordiskOzempic | $465 | $42,87030 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $202 | $40,02259 claims |
| AmgenProlia | $310 | $39,69325 claims |
| MerckIsentress | $202 | $25,54013 claims |
| Lilly USA, LLCTrulicity | $106 | $19,91518 claims |
| AstraZenecaFarxiga, Symbicort | $538 | $12,58124 claims |
| Johnson & JohnsonXarelto | $31 | $10,51311 claims |
| Boehringer IngelheimJardiance | $77 | $10,01011 claims |
| AbbVieSynthroid | $463 | $3,49237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Providence
- Aaron SamuelsProvidence$751K
- Andrew HsuProvidence$409K
- Heinrich ElinzanoProvidence$396K
- Ari PelcovitsProvidence$179K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Meghan NahassProvidence$68K
- Niharika MehtaProvidence$46K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.